POAI
Price
$0.68
Change
-$0.06 (-8.11%)
Updated
Nov 15, 03:26 PM (EDT)
SRDX
Price
$38.45
Change
+$0.36 (+0.95%)
Updated
Nov 15, 03:43 PM (EDT)
76 days until earnings call
Ad is loading...

POAI vs SRDX

Header iconPOAI vs SRDX Comparison
Open Charts POAI vs SRDXBanner chart's image
Predictive Oncology
Price$0.68
Change-$0.06 (-8.11%)
Volume$300
CapitalizationN/A
Surmodics
Price$38.45
Change+$0.36 (+0.95%)
Volume$200
CapitalizationN/A
POAI vs SRDX Comparison Chart
Loading...
POAI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SRDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
POAI vs. SRDX commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is POAI is a Hold and SRDX is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (POAI: $0.74 vs. SRDX: $38.09)
Brand notoriety: POAI and SRDX are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: POAI: 51% vs. SRDX: 69%
Market capitalization -- POAI: $9.22M vs. SRDX: $397.04M
POAI [@Medical Specialties] is valued at $9.22M. SRDX’s [@Medical Specialties] market capitalization is $397.04M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

POAI’s FA Score shows that 1 FA rating(s) are green whileSRDX’s FA Score has 0 green FA rating(s).

  • POAI’s FA Score: 1 green, 4 red.
  • SRDX’s FA Score: 0 green, 5 red.
According to our system of comparison, POAI is a better buy in the long-term than SRDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

POAI’s TA Score shows that 5 TA indicator(s) are bullish while SRDX’s TA Score has 5 bullish TA indicator(s).

  • POAI’s TA Score: 5 bullish, 3 bearish.
  • SRDX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, POAI is a better buy in the short-term than SRDX.

Price Growth

POAI (@Medical Specialties) experienced а -10.62% price change this week, while SRDX (@Medical Specialties) price change was -0.81% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -3.93%. For the same industry, the average monthly price growth was -2.52%, and the average quarterly price growth was +1.13%.

Reported Earning Dates

POAI is expected to report earnings on May 17, 2023.

SRDX is expected to report earnings on Jan 30, 2025.

Industries' Descriptions

@Medical Specialties (-3.93% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SRDX($397M) has a higher market cap than POAI($9.22M). SRDX YTD gains are higher at: 4.787 vs. POAI (-77.505). SRDX has higher annual earnings (EBITDA): 22.1M vs. POAI (-13.93M). SRDX has more cash in the bank: 35.2M vs. POAI (11.9M). POAI has less debt than SRDX: POAI (3.16M) vs SRDX (33.9M). SRDX has higher revenues than POAI: SRDX (138M) vs POAI (1.81M).
POAISRDXPOAI / SRDX
Capitalization9.22M397M2%
EBITDA-13.93M22.1M-63%
Gain YTD-77.5054.787-1,619%
P/E RatioN/A71.51-
Revenue1.81M138M1%
Total Cash11.9M35.2M34%
Total Debt3.16M33.9M9%
FUNDAMENTALS RATINGS
POAI vs SRDX: Fundamental Ratings
POAI
SRDX
OUTLOOK RATING
1..100
214
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
91
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9883
PRICE GROWTH RATING
1..100
6253
P/E GROWTH RATING
1..100
10094
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

POAI's Valuation (33) in the null industry is somewhat better than the same rating for SRDX (91) in the Medical Specialties industry. This means that POAI’s stock grew somewhat faster than SRDX’s over the last 12 months.

POAI's Profit vs Risk Rating (100) in the null industry is in the same range as SRDX (100) in the Medical Specialties industry. This means that POAI’s stock grew similarly to SRDX’s over the last 12 months.

SRDX's SMR Rating (83) in the Medical Specialties industry is in the same range as POAI (98) in the null industry. This means that SRDX’s stock grew similarly to POAI’s over the last 12 months.

SRDX's Price Growth Rating (53) in the Medical Specialties industry is in the same range as POAI (62) in the null industry. This means that SRDX’s stock grew similarly to POAI’s over the last 12 months.

SRDX's P/E Growth Rating (94) in the Medical Specialties industry is in the same range as POAI (100) in the null industry. This means that SRDX’s stock grew similarly to POAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
POAISRDX
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
64%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 9 days ago
0%
Bullish Trend 4 days ago
71%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
53%
View a ticker or compare two or three
Ad is loading...
POAI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SRDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME27.370.91
+3.44%
GameStop Corp
AAPL228.223.10
+1.38%
Apple
SPY593.35-3.84
-0.64%
SPDR® S&P 500® ETF Trust
BTC.X87250.430000-3333.734400
-3.68%
Bitcoin cryptocurrency
TSLA311.18-19.06
-5.77%
Tesla

POAI and

Correlation & Price change

A.I.dvisor tells us that POAI and SINT have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that POAI and SINT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To POAI
1D Price
Change %
POAI100%
-8.63%
SINT - POAI
30%
Poorly correlated
+0.92%
APDN - POAI
28%
Poorly correlated
-4.61%
PLSE - POAI
24%
Poorly correlated
-1.61%
SRDX - POAI
23%
Poorly correlated
-0.21%
DXCM - POAI
22%
Poorly correlated
+2.96%
More

SRDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SRDX has been loosely correlated with PXMBF. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if SRDX jumps, then PXMBF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRDX
1D Price
Change %
SRDX100%
-0.21%
PXMBF - SRDX
41%
Loosely correlated
N/A
LIVN - SRDX
39%
Loosely correlated
-2.35%
TMDX - SRDX
33%
Loosely correlated
-4.71%
UFPT - SRDX
29%
Poorly correlated
-1.72%
NARI - SRDX
28%
Poorly correlated
-3.01%
More